Say what? Translator aims at medical terminology

Thanks to the expansion of electronic health records (EHRs) and patient portals, individuals have more access to health-related data than ever. But complex medical language can often keep people from understanding much of it. To improve patients' comprehension, researchers have developed a translator of medical terminology.

The platform, called Clinical NotesAid, uses natural language processing to help explain to patients what is in their records. Working like the conventional translator—think Google Translate—Clinical NotesAid prompts users to input a passage into a box and clicking a “simplify" button. The platform then uses an array of existing systems, such as Wikipedia, to present the entered passage in layman’s terms.

“Clinical NotesAid helps patients comprehend their EHR notes by linking clinical jargon to corresponding lay terms, definitions and other related patient education materials,” according to the Clinical NotesAid website.  

Developed by Hong Yu, PhD, a professor at the University of Massachusetts Medical School’s College of Information and Computer Science, the translator hopes to increase medical literacy in patients in need. Free for public use, the platform can be used at any time by any patient, with the goal of improving healthcare to all populations.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.